NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that its Phase IIA clinical trial evaluating NV-387 Oral Gummies for the treatment of Ebola Bundibugyo virus disease in the Democratic Republic of Congo is progressing, with advancement to Phase IIB anticipated following completion of the initial study phase. Enrollment began September 23, 2026, with approximately 20 patients expected to participate in Phase IIA, which is designed to evaluate dosing regimens based on disease severity. The trial's primary endpoint is 28-day survival, and the initial phase will conclude once the final enrolled patient completes the observation period.
The announcement underscores a critical unmet medical need. The company highlighted the potential importance of an oral antiviral treatment amid the ongoing Ebola Bundibugyo outbreak, citing more than 10,000 confirmed cases and approximately 4,900 deaths in the DRC. NanoViricides stated that no treatments or vaccines are currently approved specifically for Ebola Bundibugyo and that NV-387 Oral Gummies is, to its knowledge, the only oral drug candidate undergoing clinical evaluation for the disease. This positions the company at the forefront of efforts to address a deadly pathogen with limited therapeutic options.
Beyond Ebola, NanoViricides is also evaluating NV-387 Oral Gummies in a separate Phase II clinical trial for mpox in the DRC, suggesting the drug's potential as a broad-spectrum antiviral. The company's lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. For investors, the progress of the Ebola trial represents a significant milestone in the company's pipeline and could have implications for its future licensing opportunities.
NanoViricides' business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses. The company holds a worldwide exclusive perpetual license to the TheraCour nanomedicine technology for several drugs targeting human viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. As is customary, the company notes that the path to typical drug development is extremely lengthy and requires substantial capital, and there can be no assurance that its pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development.
For more information on NanoViricides, visit www.nanoviricides.com. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC. To view the full press release, visit https://ibn.fm/JJ69W.
The announcement was distributed by BioMedWire, a specialized communications platform focused on the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For full terms of use and disclaimers, visit https://www.BioMedWire.com/Disclaimer.
